|Bid||0.5350 x 0|
|Ask||0.5250 x 0|
|Day's range||0.5200 - 0.5350|
|52-week range||0.1800 - 0.6450|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||N/A|
|Earnings date||27 Aug 2018 - 31 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Australian-based regenerative medicine company, Orthocell Ltd (ASX:OCC, "Orthocell" or the "Company"), has achieved US 510k clearance to market and supply its collagen medical device Striate+TM in the US dental bone and tissue regeneration market.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
The CEO of Orthocell Limited (ASX:OCC) is Paul Anderson, and this article examines the executive's compensation...